NKTX · CIK 1787400
What Nkarta, Inc. told the SEC could break it.
Nkarta's most acute risk is a single supplier: key steps in manufacturing its lead candidate NKX019 depend on Miltenyi's CliniMACS Plus system and reagents, available only from Miltenyi, and because those reagents expire in roughly four to six months it can't stockpile its way around the dependency. Its production is also geographically concentrated — both of its cGMP facilities sit in South San Francisco, California, so a local disruption could hit clinical and intended commercial supply at once. Underlying it all, it is a clinical-stage, pre-revenue company with no approved products, concentrating its value in unproven NK-cell programs led by NKX019 that still need substantial development and FDA approval before generating any revenue.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Sole-source dependency
- Miltenyi sole supplier of CliniMACS Plus system and reagents (short reagent shelf-life)high
Key steps of Nkarta's NKX019 manufacturing depend on the Miltenyi CliniMACS Plus system and reagents available only from Miltenyi; the reagents expire in ~4–6 months, so stockpiling can't mitigate the single-source risk.
“We are reliant on a sole supplier for certain steps of our manufacturing process. Our manufacturing process for NKX019 depends on the use of the Miltenyi CliniMACS® Plus system, and related reagents, all of which are only available from Miltenyi as the sole supplier.”
SEC filing →As of 2026
Geographic concentration
- both cGMP manufacturing facilities located in South San Francisco, CAmedium
Nkarta's clinical (and intended commercial) supply is produced at its two cGMP facilities both located in South San Francisco, California, concentrating its manufacturing in a single locale.
“We have been manufacturing clinical supply at one of our two good manufacturing practice ("cGMP") facilities located in South San Francisco, California, and intend to use our second facility in South San Francisco for additional clinical supply, supply of NKX019 or future product candidates for future pivotal clinical trials, and potential commercial supply of our product candidates.”
SEC filing →As of 2026
Other disclosures
- clinical-stage, pre-revenue, dependent on lead candidate NKX019low
Nkarta has no approved products and no product revenue; all candidates including its lead NKX019 need substantial further development and FDA approval before any commercialization, concentrating its value in unproven NK-cell programs.
“All of our product candidates, including NKX019, require substantial additional development time and resources before we would be able to apply for or receive regulatory approvals and begin generating revenue from product sales.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
Miltenyi Biotec
“Our manufacturing process for NKX019 depends on the use of the Miltenyi CliniMACS® Plus system, and related reagents, all of which are only available from Miltenyi as the sole supplier.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch